Florida Cancer Specialists and Research Institute has been awarded $2M from the Florida Cancer Innovation Fund to expand TempShield – an FDA-cleared wearable that continuously monitors body temperature in chemotherapy patients.
Why it matters:
- New ASCO data from Ellis Medicine (Roswell Park Cancer Care Network) showed TempShield use was linked to a 90% reduction in infection-related mortality and 79% fewer hospital days.
- Fevers were detected up to 72 hours before symptoms, enabling earlier intervention.
- Florida’s adoption positions the state as a potential national model for integrating proactive infection monitoring into oncology care.
Title: Long-term continuous temperature monitoring at a community cancer center: Towards a new standard of care in oncology
Authors: Tallat Mahmood, Elise Currier, Alyssa Arogosa, Mayur Pabba, Zetta Georgia Keleki, Grace Li, and Nicholas Montalto
You can read the Full Article on the Journal of Clinical Oncology.
You can find more posts about Florida Cancer Specialists and Research Institute on OncoDaily.
